Comparative Pharmacology
Head-to-head clinical analysis: CEPHRADINE versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHRADINE versus TAZICEF.
CEPHRADINE vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephradine is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
250-500 mg orally every 6 hours; 500 mg to 1 g intramuscularly or intravenously every 6 hours. Maximum: 4 g/day.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Terminal elimination half-life 0.5–1.5 hours (normal renal function); prolonged to 6–15 hours in severe renal impairment (CrCl <10 mL/min).
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Primarily renal (≥90% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<10%).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic